1-[[(4-Phenoxyphenyl)sulfonyl]amino]cyclohexanecarboxylic acid | 885269-09-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[[(4-Phenoxyphenyl)sulfonyl]amino]cyclohexanecarboxylic acid
• 英文别名: 1-[(4-phenoxyphenyl)sulfonylamino]cyclohexane-1-carboxylic acid
• CAS: 885269-09-0
• 化学式: C₁₉H₂₁NO₅S
• 分子量: 375.4
• InChiKey: SORRSTADLJXBOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Amino lactam sulfonamides as inhibitors of A-beta protein production
  申请人：——

  公开号：US20030130251A1

  公开（公告）日：2003-07-10

  This invention relates to novel lactams having the Formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式（I）的新型内酰胺及其药物组合物和使用方法。这些新化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ-肽的产生，从而防止神经性淀粉样蛋白沉积的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1218377A1

  公开（公告）日：2002-07-03
• US6503901B1
  申请人：——

  公开号：US6503901B1

  公开（公告）日：2003-01-07
• [EN] AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A beta PROTEIN PRODUCTION<br/>[FR] AMINO SULFONAMIDES DE LACTAME UTILISES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A beta
  申请人：DU PONT PHARM CO

  公开号：WO2001027091A1

  公开（公告）日：2001-04-19

  This invention relates to novel lactams having Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.